The research, published in the journal Biomedical Microdevices, tackles what many consider the single greatest limitation of organoid technology. Kidney organoids derived from human induced pluripotent stem cells, or hiPSCs, can recapitulate the early stages of human kidney development with remarkable fidelity, forming structures that resemble nephrons, the functional filtering units of the kidney. Yet without vasculature, these cellular assemblies remain stunted. The kidneys are among the most richly perfused organs in the human body, receiving between 20 and 25 percent of cardiac output, and tissue more than 100 to 200 micrometers thick simply cannot survive on oxygen and nutrient diffusion alone. Inside conventional organoid cultures, the glomerular rudiments that should eventually form blood-filtering capillary tufts typically remain avascular and disorganized, and prior studies have suggested that the absence of blood flow may even cause the regression of any endothelium that does initially appear.

The Maastricht team, led by Gabriele Addario, Chiara Formica, Lorenzo Moroni and Carlos Mota of the MERLN Institute for Technology-Inspired Regenerative Medicine, approached the problem with a hybrid strategy combining biofabrication, organoids and tissue-derived hydrogels. Their starting point was a deceptively simple manufacturing trick: sacrificial 3D printing. Rather than trying to carve channels out of a solid block, the researchers extruded thin fibers of pluronic F-127, a temperature-responsive polymer that is solid at room temperature but fluid when cold, using a nitrogen-pressure-driven bioprinter fitted with a 250-micrometer nozzle. The fibers were printed at 310 kilopascals onto a base of polydimethylsiloxane, or PDMS, a flexible silicone widely used in microfluidics. A second layer of PDMS was then pipetted over the printed template and cured overnight at 40 degrees Celsius. When the assembly was rinsed with cold phosphate-buffered saline, the pluronic dissolved away, leaving behind two hollow channels with perfectly circular cross-sections and three separate central compartments for gel, all within a fully enclosed chip.

The circular channel geometry is more than an aesthetic choice. Native capillaries are round, and the sacrificial printing approach produces this shape in a way that alternative microfabrication methods, such as stereolithography, cannot easily match. The entire manufacturing process is automated and inexpensive, which the researchers argue is essential if such platforms are to be adopted widely for drug screening.

Once the chip was fabricated, the team seeded human umbilical vein endothelial cells, or HUVECs, into the two channels, where the cells proliferated over seven days until they formed a confluent lining covering roughly 79 percent of the chip’s interior surface. Before that lining could be put to work, however, the researchers had to solve a mundane but critical problem: what to feed it. HUVECs normally thrive in endothelial growth medium, while kidney organoids require a completely different cocktail, typically Advanced RPMI supplemented with glutamine after the organoids reach a certain differentiation stage. A metabolic activity screen using a resazurin-based assay revealed that HUVECs maintained their endothelial identity, as confirmed by staining for the vessel marker CD31, even when grown in the organoid’s own Advanced RPMI medium. The 50:50 mixture of the two media, by contrast, produced the lowest metabolic activity and was abandoned.

The organoids themselves were generated through a carefully choreographed differentiation protocol. The team coaxed hiPSCs separately into two embryonic kidney progenitor populations: metanephric mesenchyme cells, which give rise to nephrons, and ureteric bud cells, which form the collecting duct system. From day 4 of differentiation onward, the two progenitor populations were combined at a one-to-one ratio in low-attachment U-bottom plates, where they self-organized into three-dimensional organoids under the influence of precisely timed growth factors including activin A, FGF9, GDNF and the BMP inhibitor LDN-193,189. By day 14, the resulting organoids contained recognizable nephron-like elements.

The pivotal innovation came with how those organoids were then embedded. In one of the chip’s three central gel compartments, organoids were suspended in a hydrogel made from partially digested decellularized extracellular matrix, or ddECM, derived from pig kidney cortex. A second compartment held organoids in the commercial matrix geltrex, and a third held organoids without any gel at all as a control. The gel-free organoids were literally washed away within days, and the geltrex-embedded organoids progressively lost their three-dimensional architecture. Only the ddECM hydrogel kept the organoids structurally intact while preserving, and even enhancing, their kidney identity. Immunostaining revealed proximal tubule structures marked by the enzyme LTL and distal tubule structures marked by the transcription factor GATA3, with confocal microscopy showing continuous connections between these tubular segments running through the organoid volume.

Proteomic analysis of the ddECM helped explain its potency. Mass spectrometry identified a suite of proteins associated with endothelial cell adhesion, migration and angiogenesis, including fibronectin and its receptor integrin beta-1, laminin subunits, vimentin and moesin. Vimentin in particular has been shown in earlier studies to mimic the activity of vascular endothelial growth factor, the master angiogenic signal, promoting both cell migration and capillary-like tube formation. Moesin, meanwhile, regulates the RhoA/ROCK signaling pathway, a critical mediator of new blood vessel sprouting. Consistent with this molecular profile, organoids embedded in ddECM showed significant upregulation of the angiogenic gene VEGFA alongside markers of epithelial, mesenchymal and podocyte cell populations, indicating that the hydrogel supported vascular development without sacrificing the organoids’ renal character.

When day-14 organoids embedded in ddECM were placed into the pre-endothelialized chip and co-cultured for five days under gentle perfusion, delivered by a rocking platform oscillating five times per minute, the results were striking. The endothelial monolayer lining the channels began to remodel, sprouting branching structures that extended toward the embedded organoids. Primitive capillary-like structures, marked by CD31, appeared not only at the organoid periphery but within its interior, invading regions that had previously been unreachable in static culture. Crucially, these nascent vessels colocalized with LTL-positive proximal tubule-like areas and PODXL-positive glomerulus-like regions, the latter being the very structures that in a real kidney house the blood-filtering capillary tuft. In control experiments, organoids cultured in ordinary U-well plates showed no branching whatsoever, and endothelialized chips maintained without organoids actually lost endothelial coverage, dropping to about 39 percent, underscoring that the organoid-hydrogel combination is what actively recruits and stabilizes the new vasculature.

The achievement represents a meaningful advance over earlier organ-on-chip attempts. A commercially available chip used in prior work placed organoids in a chamber above rectangular channels, resulting in vascularization that was largely restricted to the organoid’s outer edge. The Maastricht chip’s design, with organoids embedded directly in gel compartments flanked by circular vessels, appears to drive vascular ingenuity far deeper into the tissue. The three-compartment layout also allows multiple hydrogel formulations to be tested simultaneously within a single chip, a feature the authors note was absent from previous platforms, along with the ability to generate consistent replicates once conditions are optimized.

The broader stakes are considerable. Kidney diseases affect more than 750 million people worldwide, and the field still lacks humanized three-dimensional in vitro models robust enough for reliable drug testing. Mature, vascularized organoids could enable researchers to model chronic kidney disease and kidney fibrosis in human tissue, screen nephrotoxic drugs before they ever reach patients, and perhaps one day contribute to regenerative therapies. By supplying the missing ingredient, a functioning vasculature that grows into, rather than merely around, the organoid, the Maastricht platform moves the field a significant step closer to kidney organoids that behave less like cellular miniatures and more like the organs they are meant to emulate.

The challenge of replicating the kidney’s complex structure and multifunctional capacities in vitro has long confounded researchers, due to the organ’s composition of various specialized cell types arranged in an elaborate spatial configuration. The kidney’s ability to filter blood and produce urine hinges upon the precise organization and connectivity of nephrons—the microscopic filtering units—and the collecting ducts that channel urine to the bladder. Previous kidney organoids, though scientifically valuable, failed to faithfully reproduce these interconnected systems, limiting their applicability for studying renal physiology or pathology.

Dr. Li’s team achieved a paradigm-shifting breakthrough by integrating two distinct populations of kidney progenitor cells, which in embryonic development give rise independently to nephrons and to the urine-collecting duct system. By meticulously mimicking embryonic kidney development processes, the researchers fostered self-organization in vitro, whereby these progenitor cells autonomously aligned and connected correctly under optimized culture conditions. This novel approach yielded hSKOs exhibiting radial nephron formation linked to a central collecting system, successfully recreating the functional hierarchy and connectivity essential for kidney operation.

The team’s decade-long refinement of culture conditions was pivotal. They identified specific growth factor cocktails and nutrient environments that support the maturation and interaction of the progenitor populations. This careful optimization nurtured the differentiation and morphogenesis of the filtering units and collecting ducts, ensuring that organoids developed structural and physiological traits comparable to early-stage human kidneys. Subsequent transplantation of these organoids into murine hosts demonstrated not only enhanced maturation but also functional filtration capabilities, marking a significant leap forward in organoid-based modeling.

One of the most promising applications of hSKOs lies in their potential to elucidate mechanisms underlying kidney diseases, particularly those difficult to study due to limited access to early-stage patient tissues. CKD remains a global health burden, affecting approximately one in seven adults in the United States, with disproportionately adverse outcomes in minority populations. ADPKD, a genetic disorder characterized by large renal cysts impairing kidney function, currently lacks effective early-stage investigative models. The hSKO platform offers a dynamic window into the initial pathophysiological changes, including the onset and progression of cyst formation, with the capacity to evaluate novel therapeutic interventions at time points previously inaccessible.

Moreover, these synthetic kidney organoids open new avenues for personalized medicine and population-specific research. The USC team plans to generate hSKOs from induced pluripotent stem cell (iPSC) lines representing diverse genetic backgrounds, including Caucasian, African American, Hispanic, and Asian individuals of both sexes. This strategy will enable researchers to dissect genetic and environmental contributions to kidney diseases across populations, fostering equitable advances in nephrology.

Beyond disease modeling, hSKOs carry profound implications for pharmaceutical development. Renal toxicity is a leading cause of clinical trial failure, with about 10% of investigational drugs withdrawn due to nephrotoxic effects. The physiological relevance of these organoids promises a predictive in vitro system to screen drug candidates for kidney safety, substantially reducing the high costs and risks associated with late-stage drug attrition. Successful integration of hSKOs into preclinical pipelines could accelerate therapeutic discovery while safeguarding patient health.

Technically, the development of hSKOs capitalizes on the innate self-patterning properties of embryonic kidney progenitor cells, a concept inspired by developmental biology and molecular signaling. This bioengineering approach leverages signaling pathways such as Wnt and FGF, which orchestrate nephron and ureteric bud differentiation and branching, respectively. By employing finely-tuned gradients and timing in culture media composition, the researchers emulate in vivo conditions that dictate nephrogenesis and ductal morphogenesis, culminating in organoids with radial nephrons accurately connected to the central collecting system—a feat unattainable by prior methodologies.

The transplantation experiments conducted by the team further validated the functional integrity of these organoids. Post-implantation, hSKOs displayed gene expression patterns and hormone secretions reminiscent of native kidneys. This success indicates not only morphogenetic fidelity but also physiologic competence, suggesting that with further maturation and scaling, synthetic kidneys could one day serve as viable transplantable grafts for patients suffering renal failure.

These advances reflect a convergence of stem cell biology, bioengineering, and regenerative medicine. The USC group’s collaborative efforts, incorporating expertise across molecular genetics, nephrology, and developmental biology, illustrate the interdisciplinary nature of this research frontier. Their findings underscore the transformative potential of organoid technology to bridge gaps in disease understanding, therapeutic screening, and organ replacement strategies.

As the team progresses with their longitudinal studies, focusing on maturation dynamics and function, they anticipate uncovering critical insights into kidney development and pathology. The incorporation of cutting-edge genetic editing and single-cell transcriptomic approaches will allow unprecedented resolution in tracking disease phenotypes and responses to pharmacologic agents, positioning hSKOs as a versatile and scalable technology with broad applicability.

Looking toward the future, this pioneering work may herald an era where synthetic, patient-specific kidneys are routinely generated for transplantation, alleviating donor shortages and immune rejection issues. Until then, hSKOs are poised to become indispensable tools in the nephrology research and pharmaceutical arenas, reshaping our approach to kidney health and disease.

Subject of Research: Human synthetic kidney organoids (hSKOs/hKPAs) and their application in kidney disease modeling and regenerative medicine.

Article Title: Engineering the Future: Breakthrough Synthetic Kidney Organoids Emulate Complex Human Renal Function

News Publication Date: Not provided

Web References:

• Cell Stem Cell Publication
• CIRM Grant Details
• Science Article on Kidney Models

References: Not explicitly provided beyond web links.

Image Credits: Image by Pedro Medina/Li Lab/USC Stem Cell

Keywords: Human synthetic kidney organoids, kidney progenitor assembloids, nephrogenesis, kidney disease modeling, chronic kidney disease, autosomal-dominant polycystic kidney disease, regenerative medicine, stem cell biology, organoid transplantation, drug toxicity screening, nephron connectivity, developmental biology